• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

科威特癌症防治进展:发病率、生存率和死亡率趋势。

Progress Against Cancer in Kuwait: Trends in Incidence, Survival and Mortality.

机构信息

Epidemiology and Biostatistics, Faculty of Public Health, Kuwait University, Kuwait.

Kuwait Cancer Control Center, Ministry of Kuwait, Kuwait.

出版信息

Gulf J Oncolog. 2023 Jan;1(41):23-31.

PMID:36804156
Abstract

INTRODUCTION

To assess progress against cancer, trends in incidence, survival and mortality need to be interpreted simultaneously.

METHODS

Data were obtained from the Kuwait Cancer Registry (KCR) for all Kuwaiti children (0-14 years) and adults (15-99 years) diagnosed with one of 18 common cancers during 2000-2013, with follow-up for vital status to 31 December 2015. World-standardised average annual incidence and mortality rates were calculated for 2000-2004, 2005-2009, 2010-2013. Five-year net survival was estimated with the Pohar Perme estimator, corrected for background mortality using life tables of all-cause mortality. Survival estimates were agestandardised using the International Cancer Survival Standard weights.

RESULTS

For liver cancer, five-year net survival increased from 11.4% to 13.4% for patients diagnosed between 2000-2004 and 2010-2013, while incidence and mortality rates fell from 5.5 to 3.6 and from 3.9 to 3.0 per 100,000, respectively. Similar patterns were seen for acute lymphoblastic leukaemia (ALL) and lymphoma in children. Survival and mortality remained stable for cancers of the lung, cervix and ovary, but incidence declined from 10.2 to 7.4, 4.9 to 2.4 and 5.8 to 4.3 per 100,000, respectively. For breast cancer, survival increased from 68.3% to 75.2%, while incidence and mortality rose from 45.6 to 58.7 and from 5.8 to 12.8 per 100,000, respectively. For colon cancer, incidence and mortality rates rose from 11.4 to 12.6 and from 2.3 to 5.4 per 100,000, respectively. Five-year survival fell from 64.8% to 50.2% between 2000-2004 and 2005-2009, before rising to 58.5% for 2010-2013.

CONCLUSION

Increasing survival, alongside falling incidence and mortality rates, represents progress in cancer control, attributable to effective prevention (e.g. tobacco control and lung cancer) and early diagnostic activity (e.g. mammography for breast cancer), or better treatment (e.g. childhood ALL). The increasing prevalence of obesity, linked to rising incidence for breast and colon cancers, suggests the need for public health prevention campaigns.

摘要

简介

为了评估癌症的进展情况,需要同时解读发病率、生存率和死亡率的趋势。

方法

数据来自科威特癌症登记处(KCR),包括 2000 年至 2013 年期间在科威特被诊断患有 18 种常见癌症之一的所有儿童(0-14 岁)和成年人(15-99 岁),随访至 2015 年 12 月 31 日。计算了 2000-2004 年、2005-2009 年和 2010-2013 年期间每 100,000 人中有 18 种癌症的世界标准化平均年发病率和死亡率。使用 Pohar Perme 估计器估算了五年净生存率,并使用全因死亡率的生命表校正了背景死亡率。使用国际癌症生存标准权重对生存估计值进行了年龄标准化。

结果

对于肝癌,2000-2004 年和 2010-2013 年期间被诊断出的患者的五年净生存率从 11.4%上升至 13.4%,而发病率和死亡率分别从每 100,000 人 5.5 降至 3.6,从每 100,000 人 3.9 降至 3.0。儿童急性淋巴细胞白血病(ALL)和淋巴瘤也出现了类似的模式。肺癌、宫颈癌和卵巢癌的生存率和死亡率保持稳定,但发病率分别从每 100,000 人 10.2 降至 7.4、4.9 降至 2.4 和 5.8 降至 4.3。对于乳腺癌,生存率从 68.3%上升至 75.2%,而发病率和死亡率分别从每 100,000 人 45.6 上升至 58.7 和从每 100,000 人 5.8 上升至 12.8。结肠癌的发病率和死亡率分别从每 100,000 人 11.4 上升至 12.6 和从每 100,000 人 2.3 上升至 5.4。2000-2004 年和 2005-2009 年期间,五年生存率从 64.8%降至 50.2%,随后在 2010-2013 年升至 58.5%。

结论

生存率的提高,加上发病率和死亡率的下降,代表着癌症控制方面的进展,这归因于有效的预防措施(例如烟草控制和肺癌)和早期诊断活动(例如乳腺癌的乳房 X 光检查),或者是更好的治疗方法(例如儿童 ALL)。肥胖症的患病率不断上升,与乳腺癌和结肠癌的发病率上升有关,这表明需要开展公共卫生预防运动。

相似文献

1
Progress Against Cancer in Kuwait: Trends in Incidence, Survival and Mortality.科威特癌症防治进展:发病率、生存率和死亡率趋势。
Gulf J Oncolog. 2023 Jan;1(41):23-31.
2
Italian cancer figures--Report 2015: The burden of rare cancers in Italy.意大利癌症数据——2015年报告:意大利罕见癌症的负担
Epidemiol Prev. 2016 Jan-Feb;40(1 Suppl 2):1-120. doi: 10.19191/EP16.1S2.P001.035.
3
Cancer survival trends in Kuwait, 2000-2013: A population-based study.科威特2000 - 2013年癌症生存趋势:一项基于人群的研究。
Gulf J Oncolog. 2019 Jan;1(29):39-52.
4
Cancer Survival by Stage at Diagnosis in Kuwait: A Population-Based Study.科威特癌症诊断分期的生存率:一项基于人群的研究。
J Oncol. 2019 Sep 9;2019:8463195. doi: 10.1155/2019/8463195. eCollection 2019.
5
Italian cancer figures, report 2012: Cancer in children and adolescents.《2012年意大利癌症数据报告:儿童和青少年癌症》
Epidemiol Prev. 2013 Jan-Feb;37(1 Suppl 1):1-225.
6
Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries.全球癌症生存趋势监测 2000-14 年(CONCORD-3):对来自 71 个国家 322 个基于人群的登记处的 37513025 名诊断患有 18 种癌症之一的患者的个体记录进行分析。
Lancet. 2018 Mar 17;391(10125):1023-1075. doi: 10.1016/S0140-6736(17)33326-3. Epub 2018 Jan 31.
7
Worldwide trends in population-based survival for children, adolescents, and young adults diagnosed with leukaemia, by subtype, during 2000-14 (CONCORD-3): analysis of individual data from 258 cancer registries in 61 countries.2000 - 2014年期间,按亚型划分的全球儿童、青少年和青年白血病患者基于人群的生存率趋势(CONCORD - 3):对61个国家258个癌症登记处的个体数据进行分析。
Lancet Child Adolesc Health. 2022 Jun;6(6):409-431. doi: 10.1016/S2352-4642(22)00095-5. Epub 2022 Apr 22.
8
Reliable information for cancer control in Cali, Colombia.哥伦比亚卡利市癌症防控的可靠信息。
Colomb Med (Cali). 2018 Mar 30;49(1):23-34. doi: 10.25100/cm.v49i1.3689.
9
Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics.《国家癌症报告:第一部分:全国癌症统计数据》
Cancer. 2018 Jul 1;124(13):2785-2800. doi: 10.1002/cncr.31551. Epub 2018 May 22.
10
Measuring progress against cancer in the Azores, Portugal: Incidence, survival, and mortality trends and projections to 2025.测量葡萄牙亚速尔群岛的癌症进展:发病率、生存率和死亡率趋势及 2025 年预测。
Cancer Epidemiol. 2020 Dec;69:101810. doi: 10.1016/j.canep.2020.101810. Epub 2020 Oct 4.

引用本文的文献

1
Development of canagliflozin nanocrystals sublingual tablets in the presence of sodium caprate permeability enhancer: formulation optimization, characterization, , , and study.卡格列净纳米晶舌下片在月桂酸钠渗透促进剂存在下的研制:制剂优化、特性研究、 和 研究。
Drug Deliv. 2023 Dec;30(1):2241665. doi: 10.1080/10717544.2023.2241665.